Systolic Pressure Intervention Trial Factors Affecting Factors Affecting Atherosclerosis Study (SPRINTFAST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01475747 |
Recruitment Status :
Completed
First Posted : November 21, 2011
Last Update Posted : January 4, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Systolic Pressure Intervention Trial (SPRINT) is a large scale randomized trial of ~ 9250 adults aged 50 years or older with high cardiovascular risk sponsored by NIH. The study is designed to recruit 45% of the study population with Chronic Kidney Disease (CKD). The trial will test the effects of low systolic blood pressure (SBP) goal of < 120 mm Hg versus the standard goal of < 140 mm Hg on the primary composite of cardiovascular events and death. One of the pre-specified secondary outcome is the progression of kidney disease. In this ancillary named SPRINT - Factors affecting Atherosclerosis STudy (FAST), the investigators plan to take advantage of the unique opportunities afforded by the parent study to examine issues that are of significant public health importance.
This is an observational study in SPRINT participants. This study will examine mechanistically, the factors affecting the progression of atherosclerosis in CKD.
Condition or disease |
---|
Hypertension Chronic Kidney Disease |
Study Type : | Observational |
Actual Enrollment : | 595 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Systolic Pressure Intervention Trial (SPRINT)-Factors Affecting Factors Affecting Atherosclerosis Study (FAST) |
Study Start Date : | September 2011 |
Actual Primary Completion Date : | December 2018 |
Actual Study Completion Date : | December 2018 |

Group/Cohort |
---|
Observational - SPRINT trial subjects
Subjects in the Systolic Pressure Intervention Trial (SPRINT) observed to examine factors that affect atherosclerosis in chronic kidney disease
|
- Development Rate of Atherosclerosis [ Time Frame: Baseline and 30 months ]Correlation of the presence of CKD and rate of progression of atherosclerosis as assessed by magnetic resonance imaging (MRI) of the carotid artery.
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria
- Systolic Pressure Intervention Trial (SPRINT) participants
Exclusion Criteria
- Contraindications to MRI (such as intracranial metal prostheses, weight > 300 pounds, claustrophobia and certain types of hardware used in pacemakers, prostheses, etc.)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01475747
United States, California | |
Stanford University | |
Palo Alto, California, United States, 94340 | |
United States, Colorado | |
University of Colorado Denver | |
Denver, Colorado, United States, 80045 | |
United States, District of Columbia | |
George Washington University | |
Washington, District of Columbia, United States, 20052 | |
United States, Florida | |
Mayo Clinic Jacksonville | |
Jacksonville, Florida, United States, 32224 | |
United States, Minnesota | |
University of Minnesota | |
Minneapolis, Minnesota, United States, 55455 | |
United States, North Carolina | |
Wake Forest University | |
Winston-Salem, North Carolina, United States, 27109 | |
United States, Ohio | |
Case Western Reserve University | |
Cleveland, Ohio, United States, 44106 | |
Cleveland Clinic | |
Cleveland, Ohio, United States, 44195 | |
United States, Pennsylvania | |
University of Pennsylvania | |
Pittsburgh, Pennsylvania, United States, 15213 | |
University of Pittsburg | |
Pittsburgh, Pennsylvania, United States, 15260 | |
United States, Utah | |
University of Utah | |
Salt Lake City, Utah, United States, 84103 | |
United States, Washington | |
University of Washington | |
Seattle, Washington, United States, 98195 |
Principal Investigator: | Srinivasan Beddhu, MD | University of Utah |
Responsible Party: | Srinvasan Beddhu, MD, Assiociate Professor of Medicine, University of Utah |
ClinicalTrials.gov Identifier: | NCT01475747 |
Other Study ID Numbers: |
IRB_00049314 R01DK091437-01 ( U.S. NIH Grant/Contract ) |
First Posted: | November 21, 2011 Key Record Dates |
Last Update Posted: | January 4, 2019 |
Last Verified: | January 2019 |
Kidney Diseases Renal Insufficiency, Chronic Atherosclerosis Vascular Diseases Cardiovascular Diseases Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications |
Urogenital Diseases Male Urogenital Diseases Renal Insufficiency Chronic Disease Disease Attributes Pathologic Processes Arteriosclerosis Arterial Occlusive Diseases |